Antibodies that bind interleukin 13 and methods of use

US12358979B2 · kind B2 · utility

Assignee

• Apogee Therapeutics, Inc. · US

Inventors

• Hussam Hisham Shaheen · Lebanon, US
• Kenneth Evan Thompson · Avon Park, US
• Peter Harwin · Waltham, US
• Tomas Kiselak · Waltham, US

Key dates

• Filing date: Dec 13, 2024
• Grant date: Jul 15, 2025
• Expiry date: Dec 13, 2044

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described herein are novel and improved antibodies that bind Interleukin 13 (IL-13) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-IL-13 antibodies. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of IL-13 and/or IgE.